Literature DB >> 35932322

BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner.

Zengli Liu1, Chunxiao Hu1, Lijie Zheng1, Jialiang Liu1, Kangshuai Li1, Xingyong Li1,2, Yue Wang1, Wentao Mu1, Tianli Chen1, Anda Shi1, Bo Qiu1, Xin Zhang3, Zongli Zhang4, Yunfei Xu5.   

Abstract

BACKGROUND: Cholangiocarcinoma (CCA) is a class of malignant tumors originating from bile duct epithelial cells. Due to difficult early diagnosis and limited treatment, the prognosis of CCA is extremely poor. BMI1 is dysregulated in many human malignancies. However, the prognostic significance and oncogenic role of BMI1 in cholangiocarcinoma (CCA) are not well elucidated.
METHODS: In the present study, we investigated its clinical importance and the potential mechanisms in the progression of CCA. We detected BMI1 expression in a large CCA cohort. We demonstrated that BMI1 was substantially upregulated in CCA tissues and was identified as an independent prognostic biomarker of CCA. Moreover, overexpression of BMI1 promoted CCA proliferation, migration, and invasion. And BMI1 knockdown could inhibit proliferation and metastases of CCA in vitro and in vitro/vivo validation. Interestingly, we found that CCA-derived exosomes contain BMI1 proteins, which can transfer BMI1 between CCA cells. The unique BMI1-containing exosomes promote CCA proliferation and metastasis through autocrine/paracrine mechanisms. In addition, we demonstrated that BMI1 inhibits CD8+T cell-recruiting chemokines by promoting repressive H2A ubiquitination in CCA cells.
CONCLUSIONS: BMI1 is an unfavorable prognostic biomarker of CCA. Our data depict a novel function of BMI1 in CCA tumorigenesis and metastasis mediated by exosomes. Besides, BMI1 inhibition may augment immune checkpoint blockade to inhibit tumor progression by activating cell-intrinsic immunity of CCA.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Antitumor immunity; BMI1; Cholangiocarcinoma; Exosomes; Progression; prognosis

Mesh:

Substances:

Year:  2022        PMID: 35932322     DOI: 10.1007/s00018-022-04500-1

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.207


  47 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

Review 3.  Biliary tract cancer.

Authors:  Juan W Valle; R Katie Kelley; Bruno Nervi; Do-Youn Oh; Andrew X Zhu
Journal:  Lancet       Date:  2021-01-30       Impact factor: 79.321

4.  HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium.

Authors:  Yun-Fei Xu; Zeng-Li Liu; Chang Pan; Xiao-Qing Yang; Shang-Lei Ning; Hong-Da Liu; Sen Guo; Jin-Ming Yu; Zong-Li Zhang
Journal:  Oncogene       Date:  2018-09-03       Impact factor: 9.867

5.  The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma.

Authors:  Jialiang Liu; Guangli Ren; Kangshuai Li; Zengli Liu; Yue Wang; Tianli Chen; Wentao Mu; Xiaoqing Yang; Xingyong Li; Anda Shi; Wei Zhao; Bowen Xu; Jianhua Chang; Sen Guo; Chang Pan; Tao Zhou; Zongli Zhang; Yunfei Xu
Journal:  Cell Death Differ       Date:  2021-11-19       Impact factor: 12.067

Review 6.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

7.  WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways.

Authors:  Tianli Chen; Kangshuai Li; Zengli Liu; Jialiang Liu; Yue Wang; Rongqi Sun; Zhipeng Li; Bo Qiu; Xiaoming Zhang; Guangli Ren; Yunfei Xu; Zongli Zhang
Journal:  Mol Ther       Date:  2021-02-15       Impact factor: 12.910

8.  Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012.

Authors:  Andrea A Florio; Jacques Ferlay; Ariana Znaor; David Ruggieri; Christian S Alvarez; Mathieu Laversanne; Freddie Bray; Katherine A McGlynn; Jessica L Petrick
Journal:  Cancer       Date:  2020-03-04       Impact factor: 6.921

Review 9.  Cholangiocarcinoma: Current Knowledge and New Developments.

Authors:  Boris Blechacz
Journal:  Gut Liver       Date:  2017-01-15       Impact factor: 4.519

10.  HMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-Myc.

Authors:  Zhipeng Li; Jialiang Liu; Tianli Chen; Rongqi Sun; Zengli Liu; Bo Qiu; Yunfei Xu; Zongli Zhang
Journal:  J Exp Clin Cancer Res       Date:  2021-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.